Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Stay informed about Bionano Genomics news and developments in optical genome mapping technology. News coverage tracks the company's clinical validation studies, instrument installations, diagnostic services expansion, regulatory milestones, reimbursement developments, and research collaborations advancing genomic analysis capabilities.
Significant news categories include clinical study publications demonstrating the utility of optical genome mapping for detecting chromosomal abnormalities in hematologic malignancies and genetic disorders, announcements of new customer installations at academic medical centers and reference laboratories, and presentations at scientific conferences showcasing applications across oncology, cytogenetics, and reproductive genetics. Coverage of reimbursement policy developments, including establishment of CPT billing codes and insurance coverage decisions, impacts clinical adoption and market access for the company's diagnostic testing services.
Research collaboration announcements highlight partnerships with leading medical institutions validating optical genome mapping performance compared to conventional cytogenetic methods. Product development news covers enhancements to the Saphyr and Stratys instrument platforms, software updates to the VIA genome analysis solution, and expansion of the consumables portfolio. Regulatory clearances and quality certifications for clinical laboratory operations represent important milestones for diagnostic services growth.
Corporate developments including financial results, strategic initiatives, analyst coverage, and leadership appointments provide insight into the company's business trajectory and market position within the genomics industry. Partnership announcements with pharmaceutical companies, diagnostic laboratories, and technology providers indicate commercial momentum and expanding applications for optical genome mapping across precision medicine workflows.
Bionano Genomics, Inc. (Nasdaq: BNGO) announced a study highlighting the use of optical genome mapping (OGM) in analyzing changes in two induced pluripotent stem cell (iPSC) lines, WTC-11 and Tuba1-GFP, over 150 days. The research revealed significant genomic alterations, including hundreds of structural variants (SVs) undetected by traditional cytogenetic methods. This supports OGM's potential in regenerative medicine while raising concerns about the limitations of long-term iPSC culture. The findings accentuate OGM's value in pharmaceutical research and drug development.
Bionano Genomics (BNGO) announced the issuance of US Patent No. 11,359,244 on June 14, 2022, which covers methods for analyzing small nucleic acid fragments in nanochannel arrays. This patent relates to Bionano’s Saphyr® system, aiding in the detection of various genetic abnormalities. The technology could lead to future applications in non-invasive prenatal testing and oncology. The patent strengthens Bionano's intellectual property portfolio in genome analysis.
Bionano Genomics (BNGO) announced its participation in the EACR 2022 Congress in Seville, Spain, from June 20-23, 2022. The event will showcase Bionano's Saphyr system, NxClinical software, and expert services focused on cancer research. Key presentations will highlight the application of Optical Genome Mapping (OGM) in solid tumor analysis, including insights into pediatric CNS tumors and Ewing sarcoma. The latest NxClinical software update enhances genomic analysis capabilities for clinical researchers. This event aligns with Bionano's mission to enhance clinical research tools for cancer diagnostics.
Bionano Genomics (BNGO) showcased its Long String VANTAGE automation solution for Ultra High Molecular Weight DNA extraction at the ESHG 2022 Conference, aimed at enhancing optical genome mapping (OGM) capabilities. The collaboration with Hamilton signifies a major leap in laboratory automation efficiency. The conference featured 13 presentations highlighting OGM's role in identifying rare undiagnosed genetic diseases. CEO Erik Holmlin emphasized the potential benefits of OGM as a cost-effective and rapid alternative to traditional methods.
Bionano Genomics partnered with Hamilton to develop the Long String VANTAGE, an automated system for isolating Ultra High Molecular Weight (UHMW) DNA, enhancing throughput and quality. This innovation allows the extraction of up to 12 UHMW DNA samples in under 4 hours, double the manual output, ensuring high consistency. The collaboration aims to improve optical genome mapping applications and plans to test the system with select clinical laboratories for commercial release by the end of 2022. This automation is expected to enhance workflow efficiency in genomic analysis.
Bionano Genomics (Nasdaq: BNGO) announced a study published in Cell showcasing the effectiveness of optical genome mapping (OGM) in detecting inversions linked to genetic disorders. The research found that 80% of larger detected inversions were balanced and associated with various health issues, including pediatric autism. Analyzing 41 human samples, the study identified 40 recurrent inversions affecting 0.6% of the genome. Erik Holmlin, CEO, emphasized that OGM could make inversion analysis routine in genetic diagnostics.
Bionano Genomics (BNGO) has announced a two-hour presentation on Optical Genome Mapping (OGM) technologies by researchers from leading institutions at the Canadian College of Medical Geneticists (CCMG) General Meeting 2022, scheduled from June 6-10. The workshop, titled New Technologies and Applications of Optical Genome Mapping, will take place on June 8, featuring esteemed presenters from Columbia University Medical Center and University Health Network. This highlights Bionano's commitment to advancing genomic research and applications related to prenatal testing and cancer diagnostics.
Bionano Genomics (BNGO) will actively participate in the AGBT General Meeting 2022 in Orlando, Florida, from June 6-9. Dr. Alka Chaubey, the chief medical officer, will deliver a spotlight presentation on June 8, addressing the integration of Optical Genome Mapping (OGM) and Next Generation Sequencing (NGS) for enhanced genome analysis. Bionano is also a Bronze Sponsor and will host an evening reception, unveiling a partnership with Ignite Worldwide to promote equity in STEM. Attendees can explore live demonstrations of the Saphyr system and NxClinical software.
Bionano Genomics (Nasdaq: BNGO) announced the publication of a peer-reviewed study demonstrating the efficacy of optical genome mapping (OGM) in identifying genetic aberrations in pediatric acute myeloid leukemia (AML). Conducted by researchers at University Hospital Essen, the study analyzed samples from 24 patients, revealing that OGM detected significantly more structural variants (SVs) than traditional methods like FISH. Notably, 32 previously unknown variants were identified, with one being a high-risk marker exclusive to OGM. This research highlights OGM's potential in tracking minimal residual disease (MRD) markers crucial for treatment management.
Bionano Genomics, Inc. (BNGO) will participate virtually in the 2022 H.C. Wainwright Global Investment Conference. The presentation will be available on-demand starting May 24, 2022, at 7:00 a.m. Eastern Time. Erik Holmlin, PhD, President and CEO, will provide a company overview. Bionano specializes in optical genome mapping solutions and diagnostic software, aiming to transform genome analysis in research and medicine. Interested individuals can register for the conference and access the presentation online.
FAQ
What is the current stock price of Bionano Genomics (BNGO)?
What is the market cap of Bionano Genomics (BNGO)?
